共 50 条
- [2] PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 85 (01): : E39 - E46
- [3] CONTINUED BENEFIT TO ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER PATIENTS TREATED WITH DOSE-ESCALATED RADIATION THERAPY ACROSS MULTIPLE DEFINITIONS OF HIGH-RISK DISEASE [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04): : E335 - E344
- [4] DOSE-ESCALATED RADIOTHERAPY FOR HIGH-RISK PROSTATE CANCER: OUTCOMES IN MODERN ERA WITH SHORT-TERM ANDROGEN DEPRIVATION THERAPY [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (01): : 125 - 130
- [5] LACK OF BENEFIT FOR THE ADDITION OF ANDROGEN DEPRIVATION THERAPY TO DOSE-ESCALATED RADIOTHERAPY IN THE TREATMENT OF INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (04): : 1064 - 1071
- [6] The Addition of Low-dose-rate Brachytherapy and Androgen Deprivation Therapy Decreases Prostate Cancer Death Compared to Dose-escalated External Beam Radiation Therapy for High-risk Prostate Cancer [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S149 - S149
- [9] Association of Androgen Deprivation Therapy With Overall Survival in Men With Prostate Cancer Receiving Dose-Escalated Radiation [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S45 - S45
- [10] Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate and high risk prostate cancer [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S298 - S298